SeekingAlpha  Nov 17  Comment 
Benzinga  Aug 13  Comment 
BG Medicine, Inc. (NASDAQ: BGMD) shares tumbled 40.53 percent to $0.880 after the company priced its 2,315,654 Series A unit offering at $1 per unit and 184,346 Series B units at $1 per share. Rockwell Medical Inc (NASDAQ: RMTI) dropped 13.39...
Benzinga  Jul 8  Comment 
BG Medicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3® Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015...


BG Medicine (NASDAQ:BGMD) is a biopharmaceutical company which develops and sells diagnostic tests. These tests use biomarkers in blood tests and provide physicians which better information and accuracy on the potential disease states of patients. BG Medicine has received Food and Drug Administration (FDA) approval for one of its tests and has submitted another for approval.[1]

BG Medicine uses patient samples and data from partnerships to identify potential biomarkers the show up repeatedly for different diseases. Once they have been identified, the company builds tests to accurately measure the presence of the biomarker and runs samples to see if the biomarker is indeed relevant. After going through up to Phase III in tests, the company then submits the test to the FDA for approval.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 3, 2011. The company offered 5M shares each for $7. The inital price range was $13-$15, but the company halved the offer price. This brought the deal size to $35M. The company had originally planned to go public in December of 2010, but decided to postpone. The lead underwriter of the deal was Lazard (LAZ).[3]

For the full year 2009 the company reported a total revenue of $8.5M. During the first 9 months of 2010, the company's total revenue was $.6M. For 2009, the company had a net loss of $16M. For the first 9 months of 2010, the company had a net loss of $14M. Because the company is still heavily the in the Research & Development phase, approximately 34% of the company's costs are due to research and development.[4]


  1. BGMD S-1/A 2011 PROSPECTUS SUMMARY "Our Company" pg 1
  2. BGMD S-1/A 2011 PROSPECTUS SUMMARY "Our Solution" pg 3
  3. Renaissance Capital - IPO Home "BG Medicine prices IPO at $7, half of its original $13-$15 price range" 4 Feb 2011
  4. BGMD S-1/A 2011 PROSPECTUS SUMMARY "Summary consolidated financial data" pg 7
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki